ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0015

Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules

Shanshan Zhang1, Hideaki Tsuji1, Hui Jin2, Koji Kitagori1, Shuji Akizuki3, Kosaku Murakami1, Ran Nakashima1, Hajime Yoshifuji1, Masao Tanaka1, Hisashi Arase2, Koichiro Ohmura4 and Akio Morinobu1, 1Kyoto University, Kyoto, Japan, 2Osaka University, Osaka, Japan, 3Kyoto Universtiy, Kyoto City, Japan, 4Kobe City Medical Center General Hospital, Kobe, Japan

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), autoimmune diseases, immunology, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis (RA). We previously reported that IgG heavy chain (IgGH) was transported to the cell surface by HLA class II molecule via association with the peptide binding groove and that IgGH / HLA class II complex could be specifically recognized by RF. However, its mechanisms have not been fully understood. Here we tried to identify the binding sites of IgGH to HLA class II and recognition sites of IgGH by RF.

Methods: The heavy chain of IgG contains a variable region (VH) and 3 constant regions (CH). Each single domain (VH, CH1, CH2, and CH3) or 2~3 contiguous domains of human IgGH were sub-cloned and transfected with HLA-DR4 into HEK293T cells. The Flag-tagged IgGH domains presented by the HLA-DR molecules on the cell surface were detected by anti-Flag antibody using flow cytometry (FCM). Next, RF recognition to IgGH domains / HLA-DR complex was evaluated by FCM after RA patients’ sera and anti-human IgM antibody staining. We also made constructs of IgGH single domains linked to Cw3 peptide which binds strongly to HLA-DR4 peptide binding groove. We co-transfected the HLA-DR4 and IgGH single domains with or without Cw3 peptide then compared the IgGH fragment expression and RF reactivity.

The RF positive sera were obtained from the patients diagnosed with RA based on the ACR / EULAR criteria for RA in 2010.

Results: The expression of fragments containing CH1 on the cell surface by HLA-DR4 were equal to or rather higher than the full IgGH’s expression, while fragments without CH1 (CH2-CH3, VH, CH2 and CH3) were presented at a far lower level compared with full IgGH, especially the CH3 domain (Figure 1).

Next, among all the fragments, RF only recognized CH1-CH2-CH3 fragment besides full IgGH chain (Figure 2). On the other hand, Cw3 peptide-linked IgGH domain study revealed that RF recognized CH3 single domain linked to Cw3 peptide presented by HLA-DR4 but none of other Cw3-linked single domains were recognized (Figure 3). All of the sera from 43 RF-positive RA patients showed the same results.

Conclusion: Our data suggest that HLA-DR presents IgG heavy chain mainly by binding to CH1 domain, while RFs recognize the epitope on CH3 domain.

Figure 1. Each fragment of human IgGH was transfected with HLA-DR4 into HEK293T cells. The Flag-tagged IgGH domains presented by the HLA-DR molecules on the cell surface were detected by anti-Flag antibody using flow cytometry.

Figure 2. IgGH fragments and HLA-DR4 were co-transfected into HEK293T cells and binding of RF to IgGH domains / HLA-DR4 complex was evaluated by RA patients’ sera using flow cytometry.

Figure 3. IgGH fragments with or without Cw3 peptide were transfected with HLA-DR4 into HEK293T cells and RF reactivity to the complex with HLA-DR4 complex were compared by RA patients’ sera using flow cytometry.


Disclosures: S. Zhang, None; H. Tsuji, None; H. Jin, None; K. Kitagori, None; S. Akizuki, None; K. Murakami, None; R. Nakashima, None; H. Yoshifuji, None; M. Tanaka, None; H. Arase, None; K. Ohmura, None; A. Morinobu, None.

To cite this abstract in AMA style:

Zhang S, Tsuji H, Jin H, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Tanaka M, Arase H, Ohmura K, Morinobu A. Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-factor-recognizes-specific-domains-of-igg-heavy-chain-complexed-with-hla-class-ii-molecules/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-factor-recognizes-specific-domains-of-igg-heavy-chain-complexed-with-hla-class-ii-molecules/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology